Systems Approaches to Preventing Transplanted Cell Death in Cardiac Repair
Overview
Affiliations
Stem cell transplantation may repair the injured heart, but tissue regeneration is limited by death of transplanted cells. Most cell death occurs in the first few days post-transplantation, likely from a combination of ischemia, anoikis and inflammation. Interventions known to enhance transplanted cell survival include heat shock, over-expressing anti-apoptotic proteins, free radical scavengers, anti-inflammatory therapy and co-delivery of extracellular matrix molecules. Combinatorial use of such interventions markedly enhances graft cell survival, but death still remains a significant problem. We review these challenges to cardiac cell transplantation and present an approach to systematically address them. Most anti-death studies use histology to assess engraftment, which is time- and labor-intensive. To increase throughput, we developed two biochemical approaches to follow graft viability in the mouse heart. The first relies on LacZ enzymatic activity to track genetically modified cells, and the second quantifies human genomic DNA content using repetitive Alu sequences. Both show linear relationships between input cell number and biochemical signal, but require correction for the time lag between cell death and loss of signal. Once optimized, they permit detection of as few as 1 graft cell in 40,000 host cells. Pro-survival effects measured biochemically at three days predict long-term histological engraftment benefits. These methods permitted identification of carbamylated erythropoietin (CEPO) as a pro-survival factor for human embryonic stem cell-derived cardiomyocyte grafts. CEPO's effects were additive to heat shock, implying independent survival pathways. This system should permit combinatorial approaches to enhance graft viability in a fraction of the time required for conventional histology.
Forghani P, Liu W, Wang Z, Ling Z, Takaesu F, Yang E Biomaterials. 2025; 317:123080.
PMID: 39809079 PMC: 11788069. DOI: 10.1016/j.biomaterials.2024.123080.
Non-human primate studies for cardiomyocyte transplantation-ready for translation?.
von Bibra C, Hinkel R Front Pharmacol. 2024; 15:1408679.
PMID: 38962314 PMC: 11221829. DOI: 10.3389/fphar.2024.1408679.
Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells.
Sugiura T, Shahannaz D, Ferrell B Int J Mol Sci. 2024; 25(11).
PMID: 38891960 PMC: 11171475. DOI: 10.3390/ijms25115772.
Yang Y, Yang H, Kiskin F, Zhang J Med Rev (2021). 2024; 4(1):68-85.
PMID: 38515776 PMC: 10954298. DOI: 10.1515/mr-2023-0059.
Ameliorating orthodontic relapse using laser bio-stimulation and mesenchymal stem cells in rats.
Othman S, Saafan A, Al-Halbosiy M, Fathy I, Khursheed Alam M, El-Beialy A J Genet Eng Biotechnol. 2024; 22(1):100331.
PMID: 38494247 PMC: 10980849. DOI: 10.1016/j.jgeb.2023.100331.